Clinical trialPhase 1Recruiting
CAR-NK Cells (CL-NK-001) in Pancreatic Cancer
A Clinical Study of CAR-NK Cells (CL-NK-001) in Patients With Advanced Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 7 April 2025
- Expected end
- December 2025
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- Dose-limiting toxicity (DLT); Maximum tolerated dose (MTD); Treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (TESAE); Number of participants with abnormal clinical laboratory parameters reported as TEAE; Number of participants with abnormal vital signs reported as TEAE
- Sponsor
- Other
- Results posted
- No
- Last update
- 4 June 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a single-center, open-label, first-in-human, dose-escalation study in patients with pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
A dose-escalation study will evaluate the safety, tolerability and efficacy of CAR-NK cells (CL-NK-001) in patients with locally advanced, metastatic, or recurrent pancreatic cancer.